ETF Managers Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

ETF Managers Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,958	Closed	-$270K	–	835
2022 Q2	$270K	Buy	+18,958	New	+$292K	0.01%	617
2021 Q2	–	Sell	-33,930	Closed	-$945K	–	804
2021 Q1	$945K	Buy	+33,930	New	+$938K	0.02%	280

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ETF Managers Group's RVNC Position: Q3 2022 in Review

ETF Managers Group sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2022, closing a stake of 18,958 shares — an estimated $270K sold.

ETF Managers Group first reported a position in RVNC in Q1 2021 and held it in 2 quarters. The position peaked at $945K in Q1 2021. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

ETF Managers Group reported no remaining Revance Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
ETF Managers Group sold 18,958 Revance Therapeutics, Inc. shares in Q3 2022, an estimated $270K.
ETF Managers Group first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 2 quarters.
ETF Managers Group's Revance Therapeutics, Inc. position peaked at $945K in Q1 2021.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.